Showing results (51-60 of 66) with videos related to
Sort By:
Pageof 7
BMC Cancer|July 9, 2016
Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trialJulia Jueckstock, Brigitte Rack, Thomas W P Friedl, et al.Clinical Breast Cancer|June 19, 2023
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer PatientsMarie Tzschaschel, Thomas W P Friedl, Fabienne Schochter, et al.Human Molecular Genetics|October 21, 2019
BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cellsMuthiah Bose, Juliane Sachsenweger, Niina Laurila, et al.Archives of Gynecology and Obstetrics|September 11, 2015
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study programAmelie Schramm, Thomas W P Friedl, Fabienne Schochter, et al.International Journal of Molecular Sciences|September 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast CancerKerstin Pfister, Sophia Huesmann, Angelina Fink, et al.British Journal of Cancer|February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS CAmelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.Clinical Breast Cancer|February 14, 2017
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast CancerAmelie Schramm, Fabienne Schochter, Thomas W P Friedl, et al.Clinical Breast Cancer|March 31, 2018
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR StudyNikola S Mutschler, Christoph Scholz, Thomas W P Friedl, et al.JCO Precision Oncology|February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast CancerAmelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.Journal of the National Cancer Institute|October 13, 2018
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisElisabeth Trapp, Wolfgang Janni, Christian Schindlbeck, et al.Pageof 7